Filtered By:
Therapy: Statin Therapy
Countries: USA Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 35 results found since Jan 2013.
Can ‘toxic’ bilirubin treat a variety of illnesses?
Generations of medical and biology students have been instilled with a dim view of bilirubin. Spawned when the body trashes old red blood cells, the molecule is harmful refuse and a sign of illness. High blood levels cause jaundice, which turns the eyes and skin yellow and can signal liver trouble. Newborns can’t process the compound, and although high levels normally subside, a persistent surplus can cause brain damage.
Yet later this year up to 40 healthy Australian volunteers may begin receiving infusions of the supposedly good-for-nothing molecule. They will be participating in a phase 1 safety trial, sponsored ...
Source: ScienceNOW - June 8, 2023 Category: Science Source Type: news
Plain language summary of results from ORION-10 and ORION-11: Two studies to learn how well inclisiran works in people with high cholesterol
Future Cardiol. 2023 Jun 6. doi: 10.2217/fca-2022-0133. Online ahead of print.ABSTRACTWHAT IS THIS PLAIN LANGUAGE SUMMARY ABOUT?: This is a summary of the article describing the results of the ORION-10 and ORION-11 studies, which was published in the New England Journal of Medicine in April 2020. The studies included adult participants with atherosclerotic cardiovascular disease (ASCVD). ASCVD happens when the blood vessels that carry blood from the heart to other areas of the body are blocked by fatty build-up (plaque) causing a heart attack, stroke, or other problems. High levels of low-density lipoprotein cholesterol (L...
Source: Atherosclerosis - June 7, 2023 Category: Cardiology Authors: Kausik K Ray R Scott Wright Source Type: research
Straight from the heart: Mysterious lipids may predict cardiac problems better than cholesterol
Stephanie Blendermann, 65, had good reason to worry about heart disease. Three of her sisters died in their 40s or early 50s from heart attacks, and her father needed surgery to bypass clogged arteries. She also suffered from an autoimmune disorder that results in chronic inflammation and boosts the odds of developing cardiovascular illnesses. “I have an interesting medical chart,” says Blendermann, a real estate agent in Prior Lake, Minnesota.
Yet Blendermann’s routine lab results weren’t alarming. At checkups, her low-density lipoprotein (LDL), or “bad,” cholesterol hovered around the 100 milligrams-per-...
Source: Science of Aging Knowledge Environment - March 16, 2023 Category: Geriatrics Source Type: research
Biden ’ s Physical Says He ’ s ‘ Healthy ’ and ‘ Vigorous, ’ But ‘ Gait Remains Stiff ’
President Biden, who turned 80 in November, was examined by doctors at Walter Reed National Medical Center in Maryland on Thursday. It was his first check up in over a year. Biden, the oldest President in US history, is widely expected to announce in the coming months that he is running for re-election.
What were the results?
His physician gave him a clean bill of health, but noted Biden continues to have stiffness in his walk from a combination of arthritis in his back, neuropathy in his feet and the long-term effects of breaking his foot in November 2020 while playing with his former dog Major. Doctors conducted a routin...
Source: TIME: Health - February 16, 2023 Category: Consumer Health News Authors: Brian Bennett Tags: Uncategorized Joe Biden Longevity White House Source Type: news
Recommended and Observed Statin Use among U.S. Adults – National Health and Nutrition Examination Survey, 2011-2018
Heart disease and stroke are the first and fifth leading causes of death in the United States.1 A leading risk factor for both conditions, high blood cholesterol levels are positively associated with atherosclerotic cardiovascular disease (ASCVD).2-5 The 2013 American College of Cardiology/American Heart Association (ACC/AHA) Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (2013 Cholesterol Guideline) eliminated specific LDL-c treatment targets, shifted treatment focus to use of HMG-CoA reductase inhibitors (statins), identified four patient groups most likely to bene...
Source: Journal of Clinical Lipidology - December 24, 2022 Category: Lipidology Authors: Angela M. Thompson-Paul, Cathleen Gillespie, Hilary K. Wall, Fleetwood Loustalot, Laurence Sperling, Yuling Hong Tags: Original Research Source Type: research
What to Know About Diabetes and the Risk of Silent Heart Attacks
At first it seemed like a routine call—something the paramedics had dealt with countless times before. A man in his mid-50s was having a heart attack, and his physician had called for emergency support. But when the paramedics arrived, the physician pulled them aside and told them something peculiar: the man had no cardiovascular symptoms whatsoever.
The man had come to his doctor’s office because he’d woken early the previous morning sweating and with a sharp pain in his left wrist. These symptoms had quickly subsided and he’d gone back to sleep. Later, after going about his day, he’d visited...
Source: TIME: Health - November 4, 2022 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized healthscienceclimate heart health Source Type: news
Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease
CONCLUSIONS: Long-term LDL-C lowering with evolocumab was associated with persistently low rates of adverse events for over >8 years that did not exceed those observed in the original placebo arm during the parent study and led to further reductions in cardiovascular events compared with delayed treatment initiation.PMID:36031810 | DOI:10.1161/CIRCULATIONAHA.122.061620
Source: Circulation - August 29, 2022 Category: Cardiology Authors: Michelle L O'Donoghue Robert P Giugliano Stephen D Wiviott Dan Atar Anthony C Keech Julia F Kuder KyungAh Im Sabina A Murphy Jose H Flores-Arredondo J Antonio G Lopez Mary Elliott-Davey Bei Wang Maria Laura Monsalvo Siddique Abbasi Marc S Sabatine Source Type: research
High stroke rate in patients with medically managed asymptomatic carotid stenosis at an academic center in the Southeastern United States
Since the publication of randomized clinical trials defining the benefit of carotid endarterectomy (CEA) for asymptomatic carotid stenosis, medical management of carotid stenosis has changed significantly. With antiplatelet agents and statins, some question whether these trials are still relevant, suggesting that asymptomatic patients with>70% internal carotid artery (ICA) stenosis may do better with medial management alone, lessening the need for CEA and carotid stenting. The Vascular Quality Initiative (VQI) registry has shown that there are wide practice variations regarding the degree of stenosis that prompts surgical ...
Source: Annals of Vascular Surgery - April 22, 2022 Category: Surgery Authors: Sarah Weiner, Mary Hunter Benton, Benjana Guraziu, Yue Yange, Jie He, Yi Tang Chen, William A. Marston, Katharine L. McGinigle Tags: General Review Source Type: research
Arterial Atherosclerosis: Vascular Surgery Interventions
Am Fam Physician. 2022 Jan 1;105(1):65-72.ABSTRACTAtherosclerotic vascular disease is a leading cause of death worldwide. Atherosclerotic stenosis of the internal carotid or intracranial arteries causes up to 15% of strokes. Peripheral artery disease affects up to one in five people in the United States who are 60 years and older and nearly one-half of those who are 85 years and older. Renal artery stenosis may affect up to 5% of people with isolated hypertension and up to 40% of people with other atherosclerotic diseases. All patients with atherosclerotic vascular disease should receive a comprehensive program of guidelin...
Source: Atherosclerosis - January 14, 2022 Category: Cardiology Authors: Jonathon M Firnhaber C S Powell Source Type: research
The Projected Impact of Population-Wide Achievement of LDL Cholesterol & lt;70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD
ConclusionA substantial number of recurrent ASCVD events could be averted over 10 years if all US adults with ASCVD achieved, and maintained, an LDL-C<70 mg/dL.
Source: Cardiovascular Drugs and Therapy - October 2, 2021 Category: Cardiology Source Type: research
